Product nameAnti-Met (c-Met) antibody
See all Met (c-Met) primary antibodies
DescriptionGoat polyclonal to Met (c-Met)
Tested applicationsSuitable for: ICC/IF, Neutralising, ELISA, WBmore details
Species reactivityReacts with: Mouse, Human
Recombinant fragment (extracellular domain)(Human).
The detection limit in immunoblotting for recombinant human HGF R is approximately 5 ng/lane under non-reducing and reducing conditions. Both the alpha and beta chains of HGF R are detected by this antibody under reducing conditions. The detection limit in ELISA for recombinant human HGF R is approximately 0.16 ng/well.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferConstituents: PBS, 0.5% Trehalose
Concentration information loading...
PurityImmunogen affinity purified
Primary antibody notesThe detection limit in immunoblotting for recombinant human HGF R is approximately 5 ng/lane under non-reducing and reducing conditions. Both the alpha and beta chains of HGF R are detected by this antibody under reducing conditions. The detection limit in ELISA for recombinant human HGF R is approximately 0.16 ng/well.
Our Abpromise guarantee covers the use of ab10728 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use at an assay dependent concentration.|
|Neutralising||Use a concentration of 0.5 - 2 µg/ml. ab10728 has the ability to neutralize receptor-ligand interaction. Approximately 0.5-2 mg/mL of the antibody will block 50% of the binding of recombinant human HGF (5 ng/mL) to immobilized recombinant human HGF R/Fc Chimera (100 mL of a 1 mg/mL solution coated in each well) in an ELISA. 10 mg/mL of the antibody will block 90% of binding.|
|ELISA||Use a concentration of 0.5 - 1 µg/ml.|
|WB||Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 129 kDa.|
FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
DomainThe kinase domain is involved in SPSB1 binding.
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
- Information by UniProt
- AUTS9 antibody
- c met antibody
- D249 antibody
ab10728 staining mouse muscle cells by ICC/IF. Cells were PFA fixed and permeabilized in 0.5% Triton prior to blocking with 1% serum for 30 minutes at 25°C. The primary antibody was diluted 1/50 and incubated with the sample for 1 hour at 25°C. An Alexa Fluor® 488 conjugated chicken anti-goat antibody was used as the secondary.
This product has been referenced in:
- Morancho B et al. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res 17:106 (2015). Read more (PubMed: 26260680) »
- An N et al. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res 75:5318-28 (2015). Read more (PubMed: 26670562) »